Document:

Second Amendment to Note Purchase Agreement

 Exhibit 10.7.2 
 SYPRIS SOLUTIONS, INC. 
 SECOND AMENDMENT 
 TO NOTE PURCHASE AGREEMENT 
 $7,500,000
4.73% Senior Notes, Series A 
 Due June 30, 2009 
 $27,500,000 5.35% Senior Notes, Series B 
 Due June 30, 2011 
 $20,000,000 5.78% Senior Notes, Series C 
 Due
June 30, 2014 
 Dated as of March 13, 2006 
 To the Holders of the Senior Notes 
     of Sypris Solutions, Inc. 
     Named in the
Attached Schedule I 
 Ladies and Gentlemen: 
 Reference is made to the Note Purchase Agreement dated as of June 1, 2004, as amended by a First Amendment to Note Purchase Agreement dated as of August 3, 2005 (as so amended, the “Note Agreement”), among Sypris
Solutions, Inc., a Delaware corporation (the “Company”), and each of the Purchasers named in Schedule A thereto, pursuant to which the Company issued $7,500,000 aggregate principal amount of its 4.73% Senior Notes, Series A, due
June 30, 2009, $27,500,000 aggregate principal amount of its 5.35% Senior Notes, Series B, due June 30, 2011 and $20,000,000 aggregate principal amount of its 5.78% Senior Notes, Series C, due June 30, 2014 (together, the
“Notes”). You are referred to herein individually as a “Holder” and collectively as the “Holders.” Capitalized terms used and not otherwise defined in this Second Amendment to Note Purchase Agreement (this
“Amendment”) shall have the meanings ascribed to them in the Note Agreement, as amended hereby. 
 The Company has requested
modifications to Section 10.1 of the Note Agreement and in connection with such modifications also has agreed to a restriction on capital expenditures. The Holders have agreed to modify the Note Agreement on the terms and conditions set forth
herein. 

 In consideration of the premises and for good and valuable consideration, the receipt and sufficiency of
which are acknowledged, the Company and the Holders agree as follows: 
  

	1.	AMENDMENTS TO NOTE AGREEMENT 

 1.1. Amendment of
Section 10.1. Section 10.1 of the Note Agreement is amended to read in its entirety as follows: 
 “10.1 Consolidated
Net Debt; Fixed Charge Coverage Ratio; Capital Expenditures. 
 (a) Consolidated Net Debt. The Company will not permit the ratio of
Consolidated Net Debt to Consolidated EBITDA (for the Company’s then most recently completed four fiscal quarters) as of the last day of any fiscal quarter to be greater than the following: 
 (i) 3.25 to 1.00 for the period of four fiscal quarters ending June 30, 2005; 
 (ii) 3.75 to 1.00 for the period of four fiscal quarters ending September 30, 2005; 
 (iii) 3.25 to 1.00 for the period of four fiscal quarters ending December 31, 2005; and 
 (iv) 3.00 to 1.00 for the period of four fiscal quarters ending March 31, 2006 and for the period of four fiscal quarters ending on each fiscal
quarter thereafter. 
 (b) Fixed Charge Coverage Ratio. The Company will not permit the Fixed Charge Coverage Ratio (calculated as of
the end of the applicable fiscal quarter) for any fiscal quarter ending on or after March 31, 2006 to be less than 3.0 to 1.0. 
 (c)
Capital Expenditures. The Company will not, and will not permit any Subsidiary to, make Capital Expenditures in an amount exceeding, on a consolidated basis, (i) $30,000,000 for the fiscal year ending December 31, 2006,
(ii) $35,000,000 for the fiscal year ending December 31, 2007 and (iii) $40,000,000 for any fiscal year thereafter.” 
 1.2. Amendment of Section 11(f). Section 11(f) of the Note Agreement is amended to read in its entirety as follows: 
 “(f) (i) the Company or any Significant Subsidiary is in default (as principal or as guarantor or other surety) in the payment of any principal of or premium or make-whole amount or interest on any Debt that is outstanding in an
aggregate principal amount of at least $15,000,000 beyond any period of grace provided with respect thereto, or (ii) the Company or any Significant Subsidiary is in default in the performance of or compliance with any term of any evidence of
any 

  

 2 

 
Debt in an aggregate outstanding principal amount of at least $15,000,000 or of any mortgage, indenture or other agreement relating thereto or any other
condition exists, and as a consequence of such default or condition such Debt has become, or has been declared (or one or more Persons are entitled to declare such Debt to be), due and payable before its stated maturity or before its regularly
scheduled dates of payment, or (iii) as a consequence of the occurrence or continuation of any event or condition (other than the passage of time or the right of the holder of Debt to convert such Debt into equity interests), (x) the
Company or any Significant Subsidiary has become obligated to purchase or repay Debt before its regular maturity or before its regularly scheduled dates of payment in an aggregate outstanding principal amount of at least $15,000,000, or (y) one
or more Persons have the right to require the Company or any Significant Subsidiary so to purchase or repay such Debt; or” 
 1.3.
Schedule B. The following defined terms are added to, or restated in their entirety to read as follows in, Schedule B: 
 “Capital Expenditure” means, for any period, the consolidated sum of all expenditures by, or obligations incurred by, the Company and its Subsidiaries for an asset that will be used in a year or years subsequent to and in
the year in which the expenditure is made or obligation is incurred, and which asset is properly classified in relevant financial statements of the Company and its Subsidiaries as equipment, real property or improvements, fixed assets or a similar
type of capitalized asset, all in accordance with GAAP. 
 “Consolidated EBITDA” means, for any period, the
sum of Consolidated Net Income for such period, plus, to the extent deducted in determining such Consolidated Net Income, (i) federal, state, local and foreign income, value added and similar taxes, (ii) Consolidated Interest Expense,
(iii) depreciation and amortization expense, (iv) noncash stock compensation expense and (v) other non-cash expenses, in each case determined on a consolidated basis in accordance with GAAP. If, during the period for which
Consolidated EBITDA is being calculated, the Company or a Subsidiary has (i) acquired one or more Persons (or the assets thereof) or (ii) disposed of one or more Subsidiaries (or substantially all of the assets thereof), Consolidated
EBITDA shall be calculated on a pro forma basis (including adjustments to reflect consolidation savings) as if all of such acquisitions and all such dispositions had occurred on the first day of such period. 
 “Fixed Charge Coverage Ratio” means, as of any date, the ratio of (i) the sum of the Company’s Consolidated
EBITDA plus Operating Lease Rentals to (ii) the sum of the Company’s Consolidated Interest Expense, plus Operating Lease Rentals, in each case for the immediately preceding four fiscal quarters. 
  

 3 

	2.	REAFFIRMATION; REPRESENTATIONS AND WARRANTIES 

 2.1.
Reaffirmation of Note Agreement. The Company reaffirms its agreement to comply with each of the covenants, agreements and other provisions of the Note Agreement and the Notes, including the additions and amendments of such provisions effected
by this Amendment. 
 2.2. Note Agreement. The Company represents and warrants that the representations and warranties contained in
the Note Agreement are true and correct as of the date hereof, except (a) to the extent that any of such representations and warranties specifically relate to an earlier date and (b) for such changes, facts, transactions and occurrences
that have arisen since December 31, 2005 in the ordinary course of business, (c) such other matters as have been previously disclosed in writing by the Company (including in its financial statements and notes thereto) to the Holders and
(d) other changes that could not reasonably be expected to have a Material Adverse Effect, except for changes in Debt permitted by the Note Agreement. 
 2.3. No Default or Event of Default. After giving effect to the transactions contemplated hereby, there will exist no Default or Event of Default. 
 2.4. Authorization. The execution, delivery and performance by the Company of this Amendment have been duly authorized by all necessary corporate
action and do not require any registration with, consent or approval of, notice to or action by, any Person (including any Governmental Authority) in order to be effective and enforceable. The Note Agreement and this Amendment each constitute the
legal, valid and binding obligations of the Company, enforceable in accordance with their respective terms, except as such enforceability may be limited by (i) applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws
affecting the enforcement of creditors’ rights generally and (ii) general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). 
  

	3.	EFFECTIVE DATE 

 This Amendment shall become
effective as of the date set forth above upon the satisfaction of the following conditions: 
 3.1. Consent of Holders to this
Amendment. Execution by the Holders of at least a majority in aggregate principal amount of the Notes outstanding and receipt by the Holders of a counterpart of this Amendment duly executed by the Company. 
 3.2. Amendment of Credit Agreement. The Company shall have amended the Credit Agreement in the form attached hereto as Exhibit A, such
amendment shall be effective and the Holders shall have received a copy of an executed counterpart thereof. 
 3.3. Amendment Fee.
Each Holder shall have received payment of an amendment fee equal to 0.20% of the principal amount of the outstanding Notes held by such Holder. 
 3.4. Expenses. The Company shall have paid all fees and expenses of special counsel to the Holders. 
  

 4 

	4.	MISCELLANEOUS 

 4.1. Ratification. The Note
Agreement, as amended hereby, shall remain in full force and effect and is ratified, approved and confirmed in all respects. 
 4.2.
Reference to and Effect on the Note Agreement. Upon the final effectiveness of this Amendment, each reference in the Note Agreement and in other documents describing or referencing the Note Agreement to the “Agreement,” “Note
Agreement,” “hereunder,” “hereof,” “herein,” or words of like import referring to the Note Agreement, shall mean and be a reference to the Note Agreement, as amended hereby. 
 4.3. Binding Effect. This Amendment shall be binding upon and inure to the benefit of the respective successors and assigns of the parties hereto.

 4.4. Governing Law. This Amendment shall be governed by and construed in accordance with Illinois law, excluding choice-of-law
principles of the law of such State that would require the application of the laws of a jurisdiction other than such State. 
 4.5.
Counterparts. This Amendment may be executed in any number of counterparts, each executed counterpart constituting an original, but altogether only one instrument. 
  

 5 

 IN WITNESS WHEREOF, the Company and the Holders have caused this Amendment to be executed and
delivered by their respective officer or officers thereunto duly authorized. 
  

			
	 SYPRIS SOLUTIONS, INC.

		
	 By:
	 	 /s/ Anthony C. Allen

	 Name:
	 	 Anthony C. Allen

	 Title:
	 	 Vice President & Treasurer

  

 S-1 

 HOLDERS: 
  

			
	 THE GUARDIAN LIFE INSURANCE COMPANY OF AMERICA

		
	 By:
	 	 /s/ Ellen I. Whittaker

	 Name:
	 	 Ellen I. Whittaker

	 Title:
	 	 Director Fixed Income Investments

  

 S-2 

					
	 CONNECTICUT GENERAL LIFE INSURANCE COMPANY

		
	 By:
	 	 CIGNA Investments, Inc. (authorized agent)

			
		 	 By:
	 	 /s/ David M. Case

		 	 Name:
	 	 David M. Case

		 	 Title:
	 	 Managing Director

	
	 LIFE INSURANCE COMPANY OF NORTH AMERICA

		
	 By:
	 	 CIGNA Investments, Inc. (authorized agent)

			
		 	 By:
	 	 /s/ David M. Case

		 	 Name:
	 	 David M. Case

		 	 Title:
	 	 Managing Director

  

 S-3 

 SCHEDULE I 
  

										
	 	  	Principal Amount
	 Holder
	  	Series A	  	Series B	  	Series C
	 The Guardian Life Insurance Company of America
	  			  			  	$	20,000,000
	 Connecticut General Life Insurance Company
	  			  	$	12,000,000	  		
	 Life Insurance Company of North America
	  			  	 	8,000,000	  		
	 Jefferson Pilot Financial Insurance Company
	  	$	6,000,000	  			  		
	 Jefferson-Pilot Life Insurance Company
	  			  	 	5,000,000	  		
	 Jefferson Pilot LifeAmerica Insurance Company
	  	 	1,500,000	  	 	2,500,000	  		

  

 Schedule I 

 EXHIBIT A 
 Amendment to Credit Agreement 
  

 Exhibit AFORM OF IDEMNIFICATION AGREEMENT

 EXHIBIT 10.4 
 SCHEDULE TO INDEMNIFICATION AGREEMENT 
 The following is a list of the current directors and executive officers of Antigenics who are party to an Indemnification Agreement, the form of which was filed as Exhibit 10.4 to our registration statement on Form
S-1 (File No. 333-91747): 
 Garo H. Armen, Ph.D. 
 Pramod K. Srivastava, Ph.D. 
 Bruce Leicher 
 Renu Gupta 
 Noubar Afeyan, Ph.D. 
 Frank V, AtLee III 
 Gamil G. de Chadarevian 
 Tom Dechaene 
 Margaret Eisen 
 Wadih Jordan 
 Mark Kessel 
 Alastair Wood

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]